Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
3952
Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.
Celgene Acquires Gloucester In $340M Deal
Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition.
Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.